Abstract
The article presents current data on the use of methylprednisolone in patients with COVID-19 (COronaVIrus Disease 2019) and severe pneumonia. The author presents his own observation of patients with COVID-19 complicated by severe pneumonia, where different modes of “pulse therapy” with methylprednisolone were used. It was shown that therapy with high doses of methylprednisolone had a positive effect on the course of COVID-19 complicated by severe pneumonia. On the background of therapy with methylprednisolone in the form of a pulse, the levels of interleukin-6, C-reactive protein in the blood and the erythrocyte sedimentation rate significantly decreased. During treatment with methylprednisolone, the blood pressure level remained stable, the thermometry and the degree of blood oxygen saturation normalized. During the observation of patients with COVID-19 complicated by severe pneumonia who received methylprednisolone in the form of “pulse therapy”, no undesirable effects were noted. Hyperglycemia was transient and did not require hypoglycemic therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.